Re: Farmas USA
LIST OF DRUG CANDIDATES TARGETING NASH
http://www.nashbiotechs.com/nash-biotech-analysis/biotechs-targeting-nash/index.html
-- --
Pfizer, Bristol-Myers Squibb ( BMY.N) ,Bristol-Myers Squibb ( BMY.N) Allergan ( AGN.N,Intercept Pharmaceuticals ( ICPT.O), Galectin Therapeutics ( GALT.O), Genfit ( GNFT.PA) and Galmed Pharmaceuticals ( GLMD.O), all with a chance to be among the first to market, as well as Enanta Pharmaceuticals( ENTA.O), Durect Corp ( DRRX.O) and little-known U.K.-tradedTiziana Life Sciences ( TILST.L)
http://www.nashbiotechs.com/nash-biotech-analysis/biotechs-targeting-nash/index.html
- ----------------
The eventual market for the complex disease, formally known as Non-alcoholic Steatohepatitis, NASH is forecast to be $20 billion to $35 billion as populations with fatty diets increasingly fall victim to a condition with no approved treatments.
With intense competition and pricing pressure eroding sales of medicines for diabetes, rheumatoid arthritis and other lucrative disease categories, and an already crowded field for developmental cancer drugs, big pharma sees NASH as an enormous new market for future profit that will accelerate a wave of deal making.
